A comprehensive 2026 guide to UK online casinos with a 400% bonus. Understand wagering, find the best offers, and see if a 4x match is actually worth it. Read our full guide to 400% casino bonuses
Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK
SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief…
SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement
SinoMab BioScience Limited (SinoMab or the Company, together with its subsidiaries, the Group; HKG: 03681) is pleased to announce its annual results for the year ended 31 December 2025 (the…
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis
– Potentially a First-and Best-in-Class Product – Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety Profile SinoMab BioScience Limited (HKG: 3681, SinoMab or the Company), is pleased…
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy
SinoMab BioScience Limited (HKG: 3681, SinoMab or the Company), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases,…
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases – SinoMab BioScience Limited (HKG: 3681, SinoMab or the…
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE
Accelerating Domestic Clinical Trials and Targeting the Blue Ocean of Asthma Drugs A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment…
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company
SinoMab BioScience Limited (SinoMab or the Company, together with its subsidiaries, the Group, HKG: 3681), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics…
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China
SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological…
SinoMab Commenced Construction of its China Headquarters
Promote R&D and Marketing of Drug Candidates & Form Production and Commercialization Platform SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to…
SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress
Pipeline of Drug Candidates Has Vast Potential in the Future SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development,…